Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Oct;156(4):689-97.
doi: 10.1016/j.ahj.2008.06.001.

Effects of disclosing financial interests on participation in medical research: a randomized vignette trial

Kevin P Weinfurt  1 , Mark A Hall, Joëlle Y Friedman, Chantelle Hardy, Alice K Fortune-Greeley, Janice S Lawlor, Jennifer S Allsbrook, Li Lin, Kevin A Schulman, Jeremy Sugarman
Affiliations
Randomized Controlled Trial

Effects of disclosing financial interests on participation in medical research: a randomized vignette trial

Kevin P Weinfurt et al. Am Heart J. 2008 Oct.

Abstract

Background: Little is known about the effects of investigators' financial disclosures on potential research participants.

Methods: We conducted a vignette trial in which 470 participants in a telephone survey were randomly assigned to receive a simulated informed consent document that contained 1 of 2 financial disclosures (per capita payments to the research institution or equity ownership by the investigator) or no disclosure. The main outcome measures were trust in medical research and willingness to participate in a hypothetical clinical trial.

Results: Participants in the equity group reported less willingness to participate than participants in the per capita payments group (P = .01) and the no disclosure group (P = .03). Trust in the investigator was highest in the per capita payments group and lowest in the equity group (P < .001). Trust among participants who received no disclosure was also greater than trust among participants in the equity group (P = .04) but did not differ significantly from trust among participants in the per capita payments group (P = .15). Participants in the equity group made 3 times as many negative comments as participants in the per capita payments group; and 10 participants in the equity group spontaneously said they would not participate in the hypothetical trial because of the financial interest, compared with only 1 such participant from the other groups.

Conclusions: Although investigators' financial disclosures in research do not substantially affect willingness to participate, potential research participants are more troubled by equity interests than by per capita payments.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Recruitment Flow Diagram
See this image and copyright information in PMC

References

    1. AAMC Task Force on Financial Conflicts of Interest in Clinical Research Protecting subjects, preserving trust, promoting progress II: principles and recommendations for oversight of an institution's financial interests in human subjects research. Acad Med. 2003;78:237–45. - PubMed
    1. AAMC Task Force on Financial Conflicts of Interest in Clinical Research Protecting subjects, preserving trust, promoting progress I: policy and guidelines for the oversight of individual financial interests in human subjects research. Acad Med. 2003;78:225–36. - PubMed
    1. Financial relationships and interests in research involving human subjects: guidance for human subject protection. Fed Regist. 2004;69:26393–7.
    1. Kim SY, Millard RW, Nisbet P, et al. Potential research participants' views regarding research and institutional conflicts of interest. J Med Ethics. 2004;30:73–9. - PMC - PubMed
    1. Hampson LA, Agrawal M, Joffee S, et al. Patients' views on financial conflicts of interest in cancer research trials. N Engl J Med. 2006;355:2350–7. - PubMed

Publication types